Genitourinary Cancer
Maintenance tegafur-uracil does not improve survival in locally advanced cervical cancer
Adjuvant nivolumab plus ipilimumab does not improve survival in patients with localised RCC at high risk of relapse after nephrectomy
Triple therapy improves progression-free survival in patients with advanced RCC versus dual therapy
Adjuvant atezolizumab does not improve outcomes for patients with RCC and increased risk of recurrence
Overall survival benefit of abiraterone in mHSPC is maintained for 7 years
Limited benefit of adding long-term ADT to post-operative radiotherapy in prostate cancer
Intensified ADT benefits biochemical progression-free survival in biochemically relapsed prostate cancer
Exploratory treatment options fail in ccRCC
Adjuvant everolimus did not benefit high-risk renal cell carcinoma
Cabozantinib fails as first-line maintenance therapy in urothelial cancer
177Lu-PSMA-617 is a valid treatment option for PSMA-positive mCRPC
Enzalutamide performs well in metastatic hormone-sensitive prostate cancer
Does systematic biopsy add value to the detection rate of prostate cancer?
PSMA PET/CT cannot replace mpMRI for diagnosis of prostate cancer
Prostate cancer treatments reduce quality of life
PROpel: Good results for abiraterone plus olaparib in mCRPC
Neoadjuvant hormonal therapy promising in high-risk prostate cancer
Darolutamide performs well across subgroups in mHSPC
Shorter hospital stay with robotic surgery versus open surgery in bladder cancer
Improved risk stratification for high-risk NMIBC
Adjuvant atezolizumab may benefit ctDNA-positive patients with post-op muscle-invasive urothelial carcinoma
New prognostication in N3 penile cancer
KEYNOTE-564: Updated results of adjuvant pembrolizumab in RCC
Fewer complications with robotic surgery in renal cancer
Support for risk-adapted androgen deprivation plus high-dose radiotherapy in prostate cancer
First-line treatment with olaparib significantly improves PFS in mCRPC
First-line treatment with niraparib significantly improves PFS in HRR-mutated mCRPC
Darolutamide improves OS in mHSPC
Continued enzalutamide plus docetaxel offers clinical benefit for mCRPC patients who progress on enzalutamide
Radiohybrid PSMA PET imaging has favourable detection rate for prostate cancer recurrence
PSMA PET is a predictive biomarker in mCRPC progressing after docetaxel
Artificial intelligence improves prediction of long-term outcomes
Significant tumour response to neoadjuvant therapy in high-risk non-metastatic prostate cancer
Addition of abiraterone to ADT/docetaxel does not increase bone loss
Bavdegalutamide, a novel androgen receptor degrader, demonstrates clinical activity
No benefit of olaparib in previously untreated, platinum-ineligible, metastatic urothelial carcinoma
Rucaparib maintenance therapy extends PFS in platinum-responsive metastatic urothelial carcinoma
Positive efficacy and safety of N-803 plus BCG infusion in BCG-unresponsive NMIBC
Adding lenvatinib to pembrolizumab does not improve survival in advanced urothelial carcinoma
Maintenance niraparib fails to improve PFS in advanced urothelial cancer
First-line avelumab shows clinical activity in advanced urothelial carcinoma
Favourable pathologic response rate with neoadjuvant chemotherapy in high-risk upper tract urothelial carcinoma
Second-line nivolumab/ipilimumab boost improves ORR in metastatic urothelial carcinoma
Sacituzumab govitecan effective in platinum-refractory metastatic urothelial cancer
Neoadjuvant enfortumab vedotin promising in MIBC ineligible for cisplatin
High-risk early RCC may benefit from neoadjuvant avelumab plus axitinib
DFS benefits with adjuvant pembrolizumab in RCC persist with longer follow-up
Biomarkers predict response to immune nivolumab (± ipilimumab) in advanced RCC
Combined nivolumab/axitinib treatment elicits good response in metastatic RCC
Folliculin mutations not associated with sporadic chromophobe RCC
Differential patterns of molecular alterations among sites of metastasis in RCC
Nivolumab monotherapy represents an alternative first-line treatment option for treatment-naïve mRCC
HPV-positive and HPV-negative penile squamous cell carcinoma are molecularly distinct tumours
Atezolizumab does not improve survival in advanced penile cancer
Biomarkers to distinguish necrosis from teratoma before pcRPLND in testicular cancer
No survival benefit found in routine screening MRI for spinal cord compression in prostate cancer
Changes in genitourinary cancer management during the pandemic: findings and implications
Large phase 3 trial tests novel combinations for metastatic RCC
Positive phase-3 data for PARP inhibitor niraparib in ovarian cancer
Can nitrogen-based bisphosphonates protect against ovarian cancer?
Breast, cervical screening suboptimal in transgender individuals
Bayer’s Nubeqa drug significantly prolongs survival in prostate cancer trial
Pregnancy outcomes improving after treatment for high-grade cervical neoplasia
Brachytherapy boost may allow for shorter androgen deprivation therapy with EBRT
BRCA1/2 pathogenic variants linked to prostate, pancreatic and stomach cancers
Blacks in clinical trials respond better than whites to radiation for localized prostate cancer
Drop in PSA tied to better outcomes of apalutamide therapy in prostate cancer
Upfront immunotherapy combo means less time on treatment in advanced kidney cancer
PSA testing rose after revised USPSTF guideline, even among those deemed ineligible
Both men with high-risk non-metastatic prostate cancer and men with metastatic prostate cancer benefit from intensified hormone treatment
TKI drug-free interval strategy not detrimental to conventional continuation strategy in RCC
Modified ipilimumab schedule reduces risk of grade 3/4 adverse events
Optimal neoadjuvant dose ipilimumab/nivolumab in stage III urothelial cancer
Better survival with neoadjuvant dose-dense MVAC regimen in MIBC
PARP inhibitor rechallenge improves PFS in ovarian cancer
Pembrolizumab prolongs survival in persistent, recurrent, or metastatic cervical cancer
Pembrolizumab has durable effect in previously treated MSI-H/dMMR advanced endometrial cancer
HRR mutational status is prognostic and predictive biomarker olaparib activity
Genetic test can help pinpoint best treatment for men with high-risk prostate cancer
Shortened course of radiotherapy the new standard following prostatectomy
Androgen-annihilation therapy prolongs progression-free survival in metastatic prostate cancer
Online risk tool facilitates decision making in early, non-metastatic prostate cancer
PSMA PET imaging pinpoints most pelvic nodal metastases in high-risk prostate cancer
Pembrolizumab hikes survival by 36% at 24-month mark in cervical cancer study
Adding ADT to radiation works better than upping radiation dose for some prostate cancers
Best of EAU: Highlights on bladder cancer
ctDNA can guide adjuvant immunotherapy in muscle-invasive bladder cancer
Durvalumab ± tremelimumab by cisplatin eligibility in metastatic urothelial carcinoma
Circulating tumour cells could aid in the decision to give neoadjuvant chemotherapy
Best of EAU: New advances in testicular and penile cancer
Recommendations for the management of indeterminate small testis masses
Residual tumour resection in case of elevated markers
Best of EAU: Updates on imaging and treatment of prostate cancer
Radiographic PFS benefit of adding abiraterone to ADT and docetaxel in mCSPC
177Lu-PSMA-617: A new class of effective therapy
In women with breast or ovarian cancer, pathogenic gene variants linked with increased survival
Novel blood test plus MRI-targeted biopsy shows promise for prostate-cancer screening
Adjuvant chemotherapy does not improve outcome in patients with locally advanced cervical cancer
VISION trial shows improved survival with 177Lu-PSMA-617 in mCRPC
Novel drug combination for recurrent ovarian cancer
Abiraterone added to ADT + docetaxel nearly doubles survival in de novo mCSPC
Dual HER2-blockade shows anti-tumour activity in patients with uterine cancer
Promising efficacy and safety of feladilimab in recurrent/metastatic urothelial carcinoma
The EFFORT needed to overcome PARP resistance in ovarian cancer
Androgen blockers likely boost survival in older men with non-metastatic CR prostate cancer
Urinary thromboxane B2 may be marker of aggressive prostate cancer in Black men
Combination therapy shows promise in oligorecurrent pelvic-node relapses of prostate cancer
Common advanced prostate cancer treatments not tied to significant cognitive decline
Nicotine by-product in urine a potential biomarker of bladder cancer recurrence
MRI screening for prostate cancer prevents many unnecessary biopsies
Guideline-concordant multimodality care tied to fewer deaths in high-risk prostate cancer
Adding pembrolizumab to chemo provides little or no benefit in urothelial cancer
Adding pembrolizumab to chemo provides little or no benefit in urothelial cancer
Radical prostatectomy shifting to higher-risk cases in era of active surveillance
Adjuvant likely bests salvage radiation in high-risk prostate cancer
Genetic analysis shows race-specific tumor alterations tied to racial disparities in prostate cancer
Targeted radiotherapy improves survival in metastatic castration-resistant prostate cancer
Longer-term analysis finds survival benefit of atezolizumab in metastatic bladder cancer
Low diagnostic yield with cystoscopy and CT urography for urinary tract cancers
Patients on hormonal therapies for cancer should be monitored for heart risk – AHA
Loss of MAP3K7 and CHD1 expression drive recurrence, resistance in prostate cancer
Biologic drug nearly doubles overall survival in metastatic triple-negative breast cancer
ASCO Genitourinary Cancers Symposium: New therapy prolongs survival for patients with urothelial carcinoma
ASCO-GU Highlight: Cabozantinib plus nivolumab provides better QoL than sunitinib
Novel genomic alterations in circulating tumor cells tied to castrate-resistant prostate cancer
BRCA1/2 mutations raise risk for endometrial cancer, too
Targeting glutamine could curb castration-resistant prostate cancer
Researchers call for an overhaul of licensing and funding of anti-cancer drugs
Exploring a new strategy for metastatic germ cell tumours
Poorer outcomes in bladder cancer predicted by race/ethnicity and gender
Enfortumab vedotin as a promising treatment option for bladder cancer: phase 3 results
Enfortumab vedotin as a promising treatment option for bladder cancer: phase 2 results
New standard of care recommended for patients with upper tract urothelial cancer
Signature DNA alterations in subtypes of bladder cancer
ACE inhibitors associated with superior responses in bladder cancer
Better allocation of research dollars needed
Better prediction of favourable responses to immune checkpoint inhibitors in mUC
New prediction model for brain metastasis in germ cell tumours
Reduction in radiation exposure is possible in testicular seminoma surveillance
New therapeutic option for early metastatic seminoma
Prognosis of penile cancer associated with HPV status
Lu177 as a promising new therapy for metastatic prostate cancer
Role of prostate cancer genomics is evolving
Apalutamide prolongs progression-free survival in prostate cancer
Dose-intensified radiation therapy fails to provide better outcomes in prostate cancer
Intrinsic tumour biology may be predictive of treatment response in prostate cancer
Final TITAN trial results favour use of apalutamide
No benefit of dose-intensified salvage radiation for prostate-cancer recurrence
Adjuvant nivolumab prolongs disease-free survival in high-risk urothelial carcinoma
Apalutamide added to ADT prolongs life in men with metastatic castration-sensitive prostate cancer
Abundance of plasma cells tied to better outcomes in Blacks with prostate cancer
Uptick in diagnoses of metastatic prostate cancer tied to reduced PSA screening
Liquid biopsies helpful in prostate cancer, but most not ready for routine use
Two cases show fetus can get lung cancer during delivery if mother has cervical cancer
Platinum-based therapy could be helpful in some with advanced prostate cancer
Women with cervical cancer at increased risk of injury during diagnostic workup
Rates of bone density testing in men initiating ADT low but rising
Radiation therapy, brachytherapy outcomes similar for localized prostate cancer
HPV vaccination tied to lower risk of invasive cervical cancer
Proton-pump inhibitors may reduce benefits of atezolizumab in urothelial carcinoma
Avelumab shows survival benefit against advanced urothelial cancer
Urothelial cancer: avelumab works as maintenance therapy
ARAMIS final OS and nmCRPC safety outcomes
Final survival results from phase 3 SPARTAN trial
Novel drug for kidney cancers/VHL patients
Primary analysis from IMvigor010, adjuvant atezolizumab in high risk muscle-invasive urothelial carcinoma
First randomised trial of Lu-PSMA in mCRPC progressing after docetaxel
Follow-up confirms apalutamide survival benefits in some men with prostate cancer
Androgen deprivation appears beneficial in unfavorable intermediate-risk PC
Accurate prediction of bladder-cancer response to neoadjuvant chemotherapy remains elusive
Darolutamide lowers risk of death by 31% for some prostate-cancer patients
Ipilimumab prolongs overall survival in metastatic castration-resistant prostate cancer
Maintenance olaparib improves OS in relapsed ovarian cancer with BRCA1/2 mutation
DNA-methylation test shows promise in bladder-cancer detection, monitoring
Infertility and testis cancer risk: causal or association?
Prostatectomy: R-LRPE better than LRPE for continence
PSMA PET-CT staging is 27% more accurate
Docetaxel + hormonal therapy: improved prostate cancer PFS
ARAMIS subgroup analysis: darolutamide benefits across PSADT groups
Large patient-driven survey reveals QoL issues after prostate cancer treatment
Targeting steroid sulphatase in resistant prostate cancer cells
Good tolerance of post-RP radiotherapy ± short-term ADT
Reduced BCG frequency, faster NMIBC recurrence
Nadofaragene firadenovec effective in BCG-unresponsive papillary NMIBC
Understanding MIBC biology for novel treatment options
Ovarian cancer patients benefit from combined maintenance therapy
25% reduction in the risk of death in patients with nmCRPC treated with apalutamide
Combination of PARP inhibition plus chemotherapy in ovarian cancer
Enfortumab vedotin and pembrolizumab in advanced bladder cancer: initial results
PARP inhibition in selected patients slows progression on advanced prostate cancer
PFS extension with immunotherapy + chemotherapy in urothelial cancer
Third-line in mCRPC: CARD trial
Prostate cancer: spare radiotherapy after surgery
PFS benefit with niraparib as first-line maintenance in ovarian cancer
Enzalutamide offers survival advantage over other NSAAs in mHSPC
Benefits seen with apalutamide plus ADT in metastatic castration-sensitive prostate cancer
Enfortumab vedotin highly active in previously treated advanced urothelial carcinoma
Enzalutamide plus ADT improves outcomes for metastatic hormone-sensitive prostate cancer
Largest safety study of its kind with atezolizumab in metastatic bladder cancer
HPV and penile cancer
Prostate cancer active surveillance: Better patient risk stratification and use of imaging
Consensus treatment pathway for patients with limited pelvic lymph node involvement in otherwise localised bladder cancer
The role of pelvic lymph node dissection in prostate cancer: Extended vs standard
When to use imaging and imaging-guided therapies
FGFR3 gene mutation: Favourable prognostic impact in bladder cancer
Bladder cancer in young patients
Radioguided surgery is the future?
Spanish study directly links surgical volume with mortality in bladder cancer patients undergoing cystectomy
